Associated Papers
Haplotype-based Analysis of 6q24-25 for Association with Rheumatoid Arthritis.
Gauri LA et al.
The Journal of the Association of Physicians of India, 2024
OPRM1 Gene Polymorphism in Women with Alcohol Use Disorder.
Boroń A et al.
International Journal of Molecular Sciences, 2024
Opioid Receptor Mu 1 Gene (OPRM1) A118G Polymorphism and Emotional Modulation of Pain.
Trimble EA et al.
Journal of Pain Research, 2024
OPRM1 and BDNF polymorphisms associated with a compensatory neurophysiologic signature in knee osteoarthritis patients.
Gonçalves FT et al.
Neurophysiologie Clinique = Clinical Neurophysiology, 2023
Association between opioid and dopamine receptor gene polymorphisms OPRM1 rs1799971, DAT VNTR 9-10 repeat allele, DRD1 rs4532 and DRD2 rs1799732 and alcohol dependence: an ethnicity oriented meta-analysis.
Suresh N et al.
Pharmacogenetics and Genomics, 2023
Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.
Parada-Márquez JF et al.
Frontiers in Pharmacology, 2023
The Influence of OPRM1 A118G Polymorphism on the Dosage of Morphine in Patients with Advanced Liver Cancer.
Cheng H et al.
Journal of the College of Physicians and Surgeons--pakistan : Jcpsp, 2021
Opioid Addiction and Opioid Receptor Dimerization: Structural Modeling of the OPRD1 and OPRM1 Heterodimer and Its Signaling Pathways.
Wu B et al.
International Journal of Molecular Sciences, 2021
Population-specific genetic background for the OPRM1 variant rs1799971 (118A>G): implications for genomic medicine and functional analysis.
Levran O et al.
Molecular Psychiatry, 2021
Deleterious variants in genes regulating mammalian reproduction in Neanderthals, Denisovans and extant humans.
Greer C et al.
Human Reproduction (oxford, England), 2021
Overview of Genetic Analysis of Human Opioid Receptors.
Spampinato SM
Methods in Molecular Biology (clifton, N.j.), 2021
The μ-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers.
Cimino S et al.
Brain and Behavior, 2020
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.
Abijo T et al.
Current Neuropharmacology, 2020
Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis.
Ahmed M et al.
Journal of Molecular Neuroscience : Mn, 2018
Convergent Balancing Selection on the Mu-Opioid Receptor in Primates.
Sweeney CG et al.
Molecular Biology and Evolution, 2017
Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury.
Randesi M et al.
Cellular and Molecular Gastroenterology and Hepatology, 2017
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.
Mnika K et al.
Omics : a Journal of Integrative Biology, 2016
COMT and OPRM1 Genotype Associations with Daily Knee Pain Variability and Activity Induced Pain.
Martire LM et al.
Scandinavian Journal of Pain, 2016
[μ-Opioid Receptor Gene (OPRM1) Polymorphisms A118G and C17T in Alcohol Dependence: A Turkish Sample].
Gürel ŞC et al.
Turk Psikiyatri Dergisi = Turkish Journal of Psychiatry, 2016
A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.
Knapman A et al.
British Journal of Pharmacology, 2015
Human population genetic structure detected by pain-related mu opioid receptor gene polymorphisms.
López Soto EJ et al.
Genetics and Molecular Biology, 2015
Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).
Knapman A et al.
British Journal of Pharmacology, 2015
Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
Blum K et al.
Molecular Neurobiology, 2014
Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants.
Wang S et al.
Molecular Neurobiology, 2014
Mu opioid receptor gene: new point mutations in opioid addicts.
Dinarvand A et al.
Basic and Clinical Neuroscience, 2014
Large-scale polymorphism discovery in macaque G-protein coupled receptors.
Goswami DB et al.
Bmc Genomics, 2013
The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation.
Henker RA et al.
Biological Research for Nursing, 2013
Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.
Clarke TK et al.
Neuroscience Letters, 2013
Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Gong XD et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2013
Gender-stratified gene and gene-treatment interactions in smoking cessation.
Lee W et al.
The Pharmacogenomics Journal, 2012
Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment.
Proudnikov D et al.
The Journal of Infectious Diseases, 2012
The genetics of the opioid system and specific drug addictions.
Levran O et al.
Human Genetics, 2012
Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy.
Liu YC et al.
Cancer, 2012
The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.
Ray LA et al.
Alcoholism, Clinical and Experimental Research, 2012
A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women.
Crystal HA et al.
Addiction Biology, 2012
Genetic variability of pain perception and treatment--clinical pharmacological implications.
Lötsch J
European Journal of Clinical Pharmacology, 2011
The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs.
Fortin JP et al.
Molecular Pharmacology, 2010
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.
Mague SD et al.
Drug and Alcohol Dependence, 2010
Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction.
Deb I et al.
Journal of Neurochemistry, 2010
Identification of single nucleotide polymorphisms within exon 1 of the canine mu-opioid receptor gene.
Hawley AT et al.
Veterinary Anaesthesia and Analgesia, 2010
A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
Kim SG et al.
Psychopharmacology, 2009
G protein-coupled receptor pharmacogenetics.
Thompson MD et al.
Methods in Molecular Biology (clifton, N.j.), 2008
A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin.
Kapur S et al.
Journal of Integrative Neuroscience, 2007
The opioid system in alcohol and drug dependence: family-based association study.
Xuei X et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, 2007
Correlation of circulatory immunoglobulin levels with Mu opiate receptor allele.
Sharad S et al.
Indian Journal of Biochemistry & Biophysics, 2007
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.
Zhang H et al.
Human Molecular Genetics, 2006
[Are polymorphisms in the mu-opioid receptor important for opioid therapy?].
Lötsch J et al.
Schmerz (berlin, Germany), 2005